Efficacy and safety of dimethyl fumarate in patients with moderate-to-severe plaque psoriasis: DIMESKIN-2, a multicentre single-arm phase IIIb study

This open-label multicentre trial evaluated the efficacy and safety of oral dimethyl fumarate (DMF) in patients with moderate-to-severe plaque psoriasis in real-life clinical practice over 52 weeks. Disease severity and improvement were assessed using the psoriasis area severity index (PASI), body surface area (BSA) affected, and Physician Global Assessment (PGA). Quality of life (QoL) was assessed using the Dermatology Life Quality Index (DLQI) questionnaire. The visual analogue scale (VAS) was used to quantify pruritus and measure treatment satisfaction. A total of 141 patients were included, being 66.7% male, aged 49.1 +/- 14.7 years and with disease duration of 16 +/- 12.1 years. After 52 weeks, mean PASI decreased from 15.9 +/- 6.8 to 1.5 +/- 2 and 87.7%, 56.9% and 24.6% of patients achieved PASI 75/90/100 response, respectively. BSA decreased from 26.5 +/- 14.8% to 2.7 +/- 3.5% at 52 weeks, and 81.5% of patients had a PGA 0-1. DLQI scores decreased from 9.4 +/- 6.4 to 2.1 +/- 3.3, and VAS of pruritus decreased from 53 +/- 28.4 to 19.1 +/- 26.2 at Week 52. VAS for treatment satisfaction was 79.4 +/- 29.4 at Week 52. A total of 34.2% of patients had an AE leading to permanent discontinuation. These findings show that DMF can significantly improve indices of disease severity, pruritus and QoL, with high levels of patient satisfaction and similar safety profile to other fumarates.